Generics 10

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Dabigatran etexilate mesylate manufacturers

10 products found

Filters

10 products found

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Pradaxa®
Manufacturer #252

Manufacturer usually replies in 2 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #358
A pharmaceutical manufacturer based in the EU that is active in 70+ countries worldwide selling its products in the EU, Australia, Pacific region, and Asia for 30+ years. The company owns several manufacturing plants that comply with EU GMP requirements with production facilities for Rx products, OTC products, nutraceuticals, and medical devices. Its key therapy areas are diabetology, oncology, and neuropsychiatry. The company possesses several R&D centers with hundreds of patents and provides e-CTD format dossiers.

Manufacturer usually replies in 23 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg , 150 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Chile , Panama
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

dabigatran etexilate mesylate

Capsules 75mg, 110mg, 150mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #9258

Manufacturer usually replies in 4 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Manufacturer #21496

It's a fully integrated pharmaceutical corporation with a global reach. The company specializes in CMO and CDMO pharmaceutical preparations in a variety of dosage forms for a variety of therapeutic categories. GSK, Pfizer, Sanofi, Novartis, Mylan, Apotex, Adcock Ingram, and other MNCs manufacture formulations in various dosage forms for customers in 55 countries in important markets such as Europe, Australia & New Zealand, Canada, Japan, Far East Asia, GCC, Africa, LATAM, and CIS.

Manufacturer usually replies in 8 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #17643

Manufacturer usually replies in 8 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15176

Manufacturer usually replies in 4 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17691

Manufacturer usually replies in 7 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, WHO
Manufacturer #18119

Manufacturer usually replies in 13 days

dabigatran etexilate mesylate

Capsules 75 mg, 110 mg, 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #29381

Dabigatran etexilate mesylate:

Dabigatran etexilate mesylate is commonly referred to simply as dabigatran, where it is sold under its popular brand name of Pradaxa, among others. It is an anticoagulant medication used to treat blood clot formation and to prevent strokes in people with atrial fibrillation. It is particularly used in this function post hip or knee replacement surgery in those with a history of prior clots. As it does not require monitoring by blood tests, it has made it a choice alternative to warfarin.
Dabigatran was originally developed by a manufacturing company involved in producing pharmaceutical products, which subsequently submitted and gained it medical approval in the United States by the FDA in 2010. Currently, it is on the World Health Organization's List of Essential Medicines, indicating that it is both efficient and cost-effective, making it recommended for use in health systems across the globe. This has made it attractive for dabigatran etexilate mesylate manufacturers and dabigatran etexilate mesylate suppliers to list for sale to distributors. Where it can be found available for wholesale order across the global marketplace, at a variety of cost and price points.

Method of action of dabigatran etexilate mesylate:

Dabigatran belongs to a group of drugs that function through the inhibition of thrombin, disrupting the coagulation cascade and subsequent clotting. This is enabled through reversibly binding to the active site on the thrombin molecule, preventing thrombin-mediated activation of coagulation factors, regardless if thrombin is fibrin-bound. This makes it also capable of reducing thrombin-mediated inhibition of fibrinolysis and thus may also serve to enhance fibrinolysis.

Form and dosage of dabigatran etexilate mesylate:

The final form and packaging of dabigatran etexilate mesylate is dependent on both the manufacturers and suppliers, as well as the specific distributors and order. However, typically it is available for wholesale order in forms including capsules, tablets, and film-coated tablets. Dabigatran etexilate mesylate is a controlled substance, as such, the prescribing medical official will determine a patient-specific regime. This will be based on indications such as the underlying ailment, age, and other risk factors.

Dabigatran etexilate mesylate on Pipelinepharma:

Currently, at the time of writing, we have found 3 verified dabigatran etexilate mesylate manufacturers and dabigatran etexilate mesylate suppliers from our online global list of B2B sellers. These manufacturers, suppliers, and distributors are located in countries including India and the European Union. All listings on our online B2B database have been verified by the Pipelinepharma team according to strict quality control. This improves buyer ease and facilitates a quick and painless sourcing experience.

Price of dabigatran etexilate mesylate and how to buy:

A cursory search online reveals an approximate wholesale cost of dabigatran etexilate mesylate to be USD 46.23 for 100 x 110 mg capsules from India. However, this indicated price is vague and is not intended as a decisive guideline. The price of all pharmaceutical products is highly dependent on numerous variables such as market, organisation, manufacturers, quantity, and many others.
Although the cost of dabigatran etexilate mesylate is not normally listed on our online company B2B marketplace. The manufacturers or suppliers may choose to display a desired cost in their listing. If so, this will be indicated alongside an ‘Accept’ and ‘Negotiate’ button, with a ‘Get offer’ button being displayed in its absence. This facilitates the negotiation process by providing a baseline for expectations, expediting the sourcing experience for both parties.